Andrew Hore Quoted Micro 13 May 2019

NEX EXCHANGE National Milk Records (NMR) improved revenues from £5.32m to £5.56m in the three months to March 2019. Disease testing revenues grew at the fastest rate. This quarter did not benefit from one-off revenues like the first two quarters of the financial year. Gledhow Investments (GDH) reported a reduction in net assets to £735,000 […]

Andrew Hore – Quoted Micro 18 March 2019

NEX EXCHANGE Peel Hunt forecasts a dip in Shepherd Neame (SHEP) pre-tax profit from £11.8m to £11.2m in the year to June 2019. The broker still expects the total dividend to be increased from 29.2p a share to 30p a share. Etaireia Investments (ETIP) has suspended Ian Fellman as a non-executive director pending investigation into […]

Andrew Hore Quoted Micro 1 October 2018

NEX EXCHANGE         Brewer Shepherd Neame (SHEP) managed to edge up its profit despite flat turnover of £156.6m in the year to June 2018. Underlying pre-tax profit was 5% ahead at £11.8m. The total dividend is 3% higher at 29.2p a share. Growth came from the managed pubs but there was a decline in the […]

Andrew Hore: Quoted Micro 4th June 2018

 NEX EXCHANGE Stratmin Global Resources which was quoted AIM until August 2017, is expected to join NEX on 6 June.  Stratmin lost the AIM quotation because it failed to complete a reverse takeover, partly due to the fact that it was waiting for a promised investment. Stratmin is still in the process of completing the acquisition […]

Andrew Hore – Quoted Micro 26 March 2018

NEX EXCHANGE    Continuing revenues from renewable energy supplier Good Energy (GOOD) increased from £89.7m to £104.5m but underlying pre-tax profit was nearly two-thirds lower at £734,000 due to higher admin and interest costs. There was also a decline in gross margin. An increase in working capital meant that there was a £4.92m cash outflow […]

Buy Immupharma (IMM) says VectorVest. This pharma stock still offers further upside for the adventurous investor.

AIM listed ImmuPharma (IMM.L) is a drug discovery and development company. The London-based Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. IMM has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company’s […]

Quoted Micro 22 May 2017

NEX EXCHANGE London and south east England residential property developer St Mark Homes (SMAP) says it will in the immediate future focus on homes for sale for less than £600,000, because this is the London help to buy limit. In 2016, revenues fell from £3.1m to £1.34m but the unchanged contribution from joint ventures and […]

Quoted Micro 30 January 2017

NEX / ISDX There was a sharp improvement in operating profit from £120,006 to £213,657 at Hydro Hotel, Eastbourne (HYDP) in the year to October 2016. Revenues improved from £3.13m to £3.21m, while gross margin jumped from 9.9% to 13.6%. Pre-tax profit rose from £133,576 to £224,352. Improved marketing has helped to boost trade but […]